Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 9, 2004, Pages 1009-1017

  Koivisto, T T ^a   Rautelin, H I ^b   Voutilainen, M E ^c   Niemela S E ^d   Heikkinen, M ^e   Sipponen, P I ^f   Farkkila M A ^g  

^a SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f JORVI HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; METRONIDAZOLE; UREASE;

ADULT; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FINLAND; GASTROINTESTINAL INFECTION; GASTROSCOPY; GYNECOLOGIC INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SEX RATIO; TOOTH INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FINLAND; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 2442655091     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01930.x     Document Type: Article

References (36)

1. Valle J, Seppälä K, Sipponen P, Kosunen T. Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study. Scand J Gastroenterol 1991; 26: 1057-65.
2. Hayat M, Arora DS, Dixon MF, Clark B, O'Mahony S. Effects of Helicobacter pylori eradication on the natural history of lymphocytic gastritis. Gut 1999; 45: 495-8.
3. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7-14.
4. Kokkola A, Sipponen P, Rautelin H, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002; 16: 515-20.
5. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-8.
6. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
7. Hosking SW, Ling TK, Yung MY, et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. Bmj 1992; 305: 502-4.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
9. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia, Bmj 2002; 324: 999-1002.
10. Gee I, Playford RJ, Turner D, Sheldon N, Wicks AC. Cost analysis of breath test versus endoscopy for dyspepsia. Digestion 2002; 65: 207-12.
11. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky Muckadell de OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000; 356: 455-60.
12. van Zwet AA, de Boer WA, Schneeberger PM, Weel J, Jansz AR, Thijs JC. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur J Clin Microbiol Infect Dis 1996; 15: 861-4.
13. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN, A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
14. Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000; 14: 879-82.
15. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
16. Lopez-Brea M, Martinez MJ, Domingo D, Alarcon T. A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother 2001; 48: 295-7.
17. Kuo CH, Wu DC, Lu CY, et al. The media of rapid urease test influence the diagnosis of Helicobacter pylori. Hepatogastroenterology 2002; 49: 1191-4.
18. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Approved standard M7-A5. Informational supplemet, M100-S12, NCCLS 2002.
19. Rautelin H, Seppälä K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections, Antimicrob Agents Chemother 1992; 36: 163-6.
20. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001; 48 (Suppl. 1): 77-80.
21. Svedlund J, Sjodin I. Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
22. Lohiniemi S, Maki M, Kaukinen K, Laippala P, Collin P. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. Scand J Gastroenterol 2000; 35: 947-9.
23. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area. Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
24. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-9.
25. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24.
26. Ferrero M, Ducons JA, Sicilia B, Santolaria S, Sierra E, Gomollon F. Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. Int J Antimicrob Agents 2000; 16: 245-8.
27. Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
28. Glupczynski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-52.
29. Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35: 1562-6.
30. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995: 9 (Suppl 2): 33-9.
31. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473-8.
32. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998; 43 (Suppl 1): S61-5.
33. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-82.
34. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
35. Tilastokeskus. Statistical Yearbook of Finland 2003, Jyväskylä: Gummerus Kirjapaino Oy, 2003.
36. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20.